Takeda Pharmaceutical Company Limited
[Takeda Pharmaceutical] Fiscal Year 2026 Financial Results | Sales approximately JPY 4.5 trillion, Net profit JPY 1.66 trillion
Takeda Pharmaceutical's FY2026 financial results are projected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, showing an increase compared to the same period last year. Adjustments for litigation reserves and business restructuring expenses are also reflected.
Key Figures
- Sales Revenue: JPY 4.64 trillion (YoY +3.0%)
- Net Income Attributable to Owners of Parent: JPY 1.006 trillion (YoY +318.4 billion yen)
- Dividend Forecast: JPY 204 (planned increase)
AI要約
Performance Overview
Takeda Pharmaceutical's FY2026 financial results are expected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, representing an increase from the same period last year. Despite adjustments for litigation reserves and restructuring expenses, the company maintains steady growth. Revenue has increased driven by strong sales of new and existing products, and net income has improved significantly. Considering potential litigation risks and currency fluctuations, the company aims for stable growth based on its long-term strategic plan.
Future Outlook and Impact on Shareholders
Takeda Pharmaceutical anticipates continued growth in sales and profits in FY2026, promoting R&D and new drug launches while managing litigation risks and business restructuring costs. The company plans to increase dividends by JPY 204 per share, emphasizing shareholder returns. While remaining cautious of currency risks and regulatory changes, Takeda will continue its strategy focused on long-term growth and value enhancement.
Takeda Pharmaceutical Company Limited
Company overview · Stock price · Financial data · All IR
